The landscape of oral SERDs and their potential in ER+ breast cancer [Video]

Erika Hamilton, MD, from Sarah Cannon Research Institute in Nashville, TN, discusses the landscape of oral Selective Estrogen Receptor Degraders (SERDs) and their potential in ER+ breast cancer. These compounds work by degrading the estrogen receptor, providing a new endocrine backbone for treating ER-positive breast cancer. Notable developments include elacestrant, FDA-approved for patients with ESR1 mutations, and positive data from camizestrant, which is in confirmatory trials. Trials are exploring the use of SERDs post-CDK4/6 inhibitors, in combination with CDK4/6 inhibitors in the first-line setting, and in adjuvant therapy, either upfront or as a switch strategy. These advancements offer exciting prospects for treating ER+ breast cancer. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.